<?xml version="1.0" encoding="UTF-8"?>
<p id="Par31">There are currently no licensed therapeutics or vaccines for SARS or MERS. Consequently, supportive care is the mainstay of treatment [
 <xref ref-type="bibr" rid="CR142">142</xref>]. Renal replacement therapy is frequently required in severe illness [
 <xref ref-type="bibr" rid="CR119">119</xref>, 
 <xref ref-type="bibr" rid="CR143">143</xref>, 
 <xref ref-type="bibr" rid="CR144">144</xref>]. Empiric antibiotics are often administered given potential for secondary bacterial infection. Ribavirin and pegylated interferon alpha 2b have been administered to MERS patients, although effectiveness data is lacking [
 <xref ref-type="bibr" rid="CR144">144</xref>]. Aerosol-generating procedures including endotracheal intubation are associated with increased risk of healthcare worker infection necessitating strict adherence to infection control measures, including use of eye protection in addition to standard, airborne, and contact precautions [
 <xref ref-type="bibr" rid="CR145">145</xref>].
</p>
